Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor recept...

por Metro, Giulio, Bonaiti, Angelo, Birocchi, Ilaria, Marasciulo, Francesca, Ubaldi, Martina, Metelli, Niccolò, Minotti, Vincenzo, Addeo, Alfredo
Publicado 2022

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a C...

por Baglivo, Sara, Mandarano, Martina, Bellezza, Guido, Minotti, Vincenzo, Bonaiti, Angelo, Fischer, Matthias J., Birocchi, Ilaria, Roila, Fausto, Metelli, Niccolò, Ludovini, Vienna, Metro, Giulio
Publicado 2022

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real...

por Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Paglialunga, Luca, Gatta Michelet, Marta Rita, Lavacchi, Daniele, Berardi, Rossana, Mentrasti, Giulia, Metro, Giulio, Birocchi, Ilaria, Delmonte, Angelo, Priano, Ilaria, Comin, Camilla Eva, Castiglione, Francesca, Bartoli, Caterina, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Publicado 2022